EXDI Exactus Inc

Exactus, Inc. Research Report Published by Proactive Investors

Exactus, Inc. Research Report Published by Proactive Investors

DELRAY BEACH, Fla., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Exactus, Inc. (OTCQB:EXDI) (the “Company”), a farmer and manufacturer of hemp-derived phytocannabinoid products, today announced that Proactive Investors published a research report about the company on October 24, 2019. 

The report was written by Emma Ulker, an equity analyst that has over 15 years of experience mainly across the bio-tech, pharma and med tech sectors and can be found and downloaded using the following link:

Proactive Investors enables companies and investors to connect intelligently. Proactive is one of the fastest growing financial media portals in the world, providing breaking news, commentary and analysis on hundreds of listed companies and pre-IPO businesses across the globe, 24/7.

To learn more about Exactus, Inc., visit the corporate website at  and the e-commerce website at .

About Exactus:

Exactus Inc. is dedicated to introducing hemp-derived phytocannabinoid products into mainstream consumer markets. The Company has made investments in farming and has over 200 acres of CBD-rich hemp in Southwest Oregon. The Company is introducing a range of consumer brands, such as Green Goddess Extracts, Phenologie, Paradise CBD and Exactus. Hemp is a legal type of cannabis plant containing less than 0.3% THC (tetrahydrocannabinol), which is the psychoactive component of the cannabis plant. After 40 years of prohibition, the Agricultural Improvement Act of 2018, known as the 2018 Farm Bill, legalized hemp at the federal level. Hemp production will be regulated by the United States Department of Agriculture (USDA) and the states. As a result, in 2019 hemp was generally removed from the Controlled Substances Act (CSA) and enforcement by the Drug Enforcement Administration (DEA).

For more information about Exactus: .

Investor Notice

Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks, uncertainties and forward-looking statements described under "Risk Factors" in Item 1A of our most recent Form 10-K for the fiscal year ended December 31, 2018 filed with the Securities and Exchange Commission (the "SEC") on March 29, 2019, and in other periodic and current reports we file with the SEC.  If any of these risks were to occur, our business, financial condition, or results of operations would likely suffer. In that event, the value of our securities could decline, and you could lose part or all of your investment. The risks and uncertainties we describe are not the only ones facing us. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. In addition, our past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results in the future. See "Safe Harbor" below.

Safe Harbor - Forward-Looking Statements

The information provided in this press release may include forward-looking statements relating to future events or the future financial performance of the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company's periodic and current filings with the SEC, including the factors described in the sections entitled "Risk Factors", copies of which may be obtained from the SEC's website at Any forward-looking statement speaks only as of the date on which such statement is made, and the Company does not intend to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise.

Company Contact:

Andrew Johnson

Chief Strategy Officer

Exactus Inc.

509-999-9695

EN
28/10/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Exactus Inc

 PRESS RELEASE

Exactus, Inc. Reports Second Quarter 2020 Financial Results and Confer...

Exactus, Inc. Reports Second Quarter 2020 Financial Results and Conference Call Second Quarter 2020 Highlights Total Net Revenue of $531,240Continuation of Sales & Marketing BuildoutWhite Label Division LaunchEuropean Sales ExpansionStrengthened the Balance Sheet DELRAY BEACH, Fla., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Exactus, Inc. (OTCQB: EXDI) (the “Company”) a leading supplier of hemp-derived ingredients (CBD/CBG) and feminized hemp genetics, reported its financial results for the second quarter 2020 and conference call dial-in information. During the second quarter of 2020, Exactus c...

 PRESS RELEASE

Exactus, Inc. Reports First Quarter 2020 Financial Results

Exactus, Inc. Reports First Quarter 2020 Financial Results First Quarter 2020 Highlights Total Net Revenue of $836,000Continuation of Sales & Marketing BuildoutRestructuring of Company and Board of DirectorsBegan Biomass Inventory Extraction ProcessDuring Q2 2020, The Company Received PPP Funds and an SBA Loan DELRAY BEACH, Fla., July 01, 2020 (GLOBE NEWSWIRE) -- Exactus, Inc. (OTCQB: EXDI) (the “Company”) a leading supplier of hemp-derived ingredients (CBD/CBG) and feminized hemp genetics, today reported financial results for the first quarter 2020. During the first quarter of 2020, E...

 PRESS RELEASE

Exactus Appoints Leading Business Expert, Julian Pittam to Chairman of...

Exactus Appoints Leading Business Expert, Julian Pittam to Chairman of the Board of Directors DELRAY BEACH, Fla., June 15, 2020 (GLOBE NEWSWIRE) -- Exactus, Inc. (OTCQB: EXDI) (the “Company”) a leading supplier of hemp-derived ingredients (CBD) and feminized hemp genetics, announced today the appointment of executive business leader, Julian Pittam to the Chairman of the Board. “Julian Pittam has been an investor and a friendly voice of wisdom since our inception, and we are honored to have him join as Chairman of the Board at this pivotal moment,” said Emiliano Aloi, Exactus Interim Chie...

 PRESS RELEASE

Exactus Announces its Hemp Seed Buyback Program to Assist Farmers Impa...

Exactus Announces its Hemp Seed Buyback Program to Assist Farmers Impacted by the COVID-19 Pandemic DELRAY BEACH, Fla., May 28, 2020 (GLOBE NEWSWIRE) -- Exactus, Inc. (OTCQB: EXDI) (the “Company”) a leading supplier of hemp-derived ingredients (CBD) and feminized hemp genetics, announced today the institution of its Exactus Hemp Buyback Program in support of farmers who purchase seeds from the company. Exactus introduced its buyback program during this essential hemp planting season to aid farmers faced with hardships caused by the COVID-19 pandemic. With the launch of its buyback progra...

 PRESS RELEASE

Exactus, Inc. Reports 2019 Year End Results

Exactus, Inc. Reports 2019 Year End Results Year End 2019 Highlights Completed first harvestEntered into multiple supply agreements with industry leadersBuilt a foundation for mainstream adoptionSolidified our footprint in the hemp industryDuring Q1 2020, purchase orders for approximately $900,000 of CBD and CBG products have been received. DELRAY BEACH, Fla., May 26, 2020 (GLOBE NEWSWIRE) -- Exactus, Inc. (OTCQB: EXDI) (the “Company”) a leading supplier of hemp-derived ingredients (CBD/CBG) and feminized hemp genetics, today reported financial results for the year end 2019. Duri...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch